K Rickels

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study
    Olga Brawman-Mintzer
    Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29406, USA
    J Clin Psychiatry 67:874-81. 2006
  2. doi request reprint Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    J Clin Psychopharmacol 28:235-9. 2008
  3. doi request reprint Physician Withdrawal Checklist (PWC-20)
    Karl Rickels
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 28:447-51. 2008
  4. ncbi request reprint Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial
    Karl Rickels
    Department of Psychiatry, Mood and Anxiety Disorders Section, University of Pennsylvania, Philadelphia, PA 19104 3309, USA
    J Clin Psychiatry 70:326-33. 2009
  5. doi request reprint Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment
    Karl Rickels
    Department of Psychiatry, Mood and Anxiety Disorders Section, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Int Clin Psychopharmacol 27:142-50. 2012
  6. pmc Consumer advertising can be misleading
    Karl Rickels
    PLoS Med 3:e119; author reply e116. 2006
  7. ncbi request reprint Pharmacotherapy of generalized anxiety disorder
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia, USA
    J Clin Psychiatry 63:9-16. 2002
  8. ncbi request reprint Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia 19104 3309, USA
    Arch Gen Psychiatry 62:1022-30. 2005
  9. doi request reprint Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Arch Gen Psychiatry 67:1274-81. 2010
  10. ncbi request reprint Alprazolam extended-release in panic disorder
    Karl Rickels
    University of Pennsylvania, Department of Psychiatry, University of Pennsylvania Medical Center, PA 19104 3309, USA
    Expert Opin Pharmacother 5:1599-611. 2004

Research Grants

  1. Short-Term vs Long-Term Treatment for GAD
    Karl Rickels; Fiscal Year: 2004
  2. Short-Term vs Long-Term Treatment for GAD
    Karl Rickels; Fiscal Year: 2005
  3. Short-Term vs Long-Term Treatment for GAD
    Karl Rickels; Fiscal Year: 2006
  4. Short-Term vs Long-Term Treatment for GAD
    Karl Rickels; Fiscal Year: 2007

Detail Information

Publications50

  1. ncbi request reprint Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study
    Olga Brawman-Mintzer
    Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29406, USA
    J Clin Psychiatry 67:874-81. 2006
    ..This study assessed the efficacy and safety of sertraline in the treatment of generalized anxiety disorder (GAD)...
  2. doi request reprint Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    J Clin Psychopharmacol 28:235-9. 2008
    ..Collectively, these results support further clinical investigation of higher doses of PRX-00023 in anxiety and depression...
  3. doi request reprint Physician Withdrawal Checklist (PWC-20)
    Karl Rickels
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 28:447-51. 2008
    ..Our results suggest that the Penn Physician Withdrawal Checklist is a simple and accurate method to assess anxiolytic discontinuation symptoms...
  4. ncbi request reprint Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial
    Karl Rickels
    Department of Psychiatry, Mood and Anxiety Disorders Section, University of Pennsylvania, Philadelphia, PA 19104 3309, USA
    J Clin Psychiatry 70:326-33. 2009
    ..The efficacy and tolerability of vilazodone, a combined selective serotonin reuptake inhibitor and partial 5-hydroxytryptamine-1A (5-HT(1A)) receptor agonist, were evaluated in adult patients with major depressive disorder (MDD)...
  5. doi request reprint Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment
    Karl Rickels
    Department of Psychiatry, Mood and Anxiety Disorders Section, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Int Clin Psychopharmacol 27:142-50. 2012
    ..3%). The study was discontinued early after an interim analysis. The results indicate that adjunctive pregabalin is an efficacious therapy for patients with GAD who experience an inadequate response to established treatments...
  6. pmc Consumer advertising can be misleading
    Karl Rickels
    PLoS Med 3:e119; author reply e116. 2006
  7. ncbi request reprint Pharmacotherapy of generalized anxiety disorder
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia, USA
    J Clin Psychiatry 63:9-16. 2002
    ..Remission rates are still only about 40%, signifying the need for improved treatment interventions...
  8. ncbi request reprint Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia 19104 3309, USA
    Arch Gen Psychiatry 62:1022-30. 2005
    ..Pregabalin inhibits release of excess excitatory neurotransmitters, presumably by binding to the alpha2-delta subunit protein of widely distributed voltage-dependent calcium channels in the brain and spinal cord...
  9. doi request reprint Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Arch Gen Psychiatry 67:1274-81. 2010
    ..Generalized anxiety disorder (GAD) is a chronic disorder in need of reliable data to guide long-term treatment...
  10. ncbi request reprint Alprazolam extended-release in panic disorder
    Karl Rickels
    University of Pennsylvania, Department of Psychiatry, University of Pennsylvania Medical Center, PA 19104 3309, USA
    Expert Opin Pharmacother 5:1599-611. 2004
    ..It should be noted that long-term therapy with alprazolam-XR carries the same risk of dependence and withdrawal during discontinuation as the original formulation of alprazolam...
  11. ncbi request reprint A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania Medical Center, Philadelphia, PA 19104 3309, USA
    J Clin Psychopharmacol 24:488-96. 2004
    ..Venlafaxine ER was safe, well tolerated, and efficacious in the short-term treatment of generalized social anxiety disorder...
  12. doi request reprint Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 30:18-24. 2010
    ..To compare the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) with placebo in reducing relapse rate in patients with major depressive disorder (MDD)...
  13. ncbi request reprint Assessment of anxiety and depression in primary care: value of a four-item questionnaire
    Michael R Rickels
    Mood and Anxiety Disorders Section, Department of PsychiatryUniversity of Pennsylvania School of Medicine, 3535 Market St, Philadelphia, PA 19104 3309, USA
    J Am Osteopath Assoc 109:216-9. 2009
    ..However, such survey tools are typically lengthy and are therefore not used often in primary care...
  14. ncbi request reprint What is generalized anxiety disorder?
    K Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia 19104, USA
    J Clin Psychiatry 62:4-12; discussion 13-4. 2001
    ..The impact of the changes in diagnostic criteria on research into GAD, and on diagnosis, differential diagnosis, and treatment of GAD, will be discussed...
  15. ncbi request reprint Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy
    K Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia, USA
    Am J Psychiatry 157:1973-9. 2000
    ..5 years) were enrolled in a benzodiazepine discontinuation program that assessed the effectiveness of concomitant imipramine (180 mg/day) and buspirone (38 mg/day) compared to placebo in facilitating benzodiazepine discontinuation...
  16. ncbi request reprint Overview and clinical presentation of generalized anxiety disorder
    K Rickels
    Section of Mood and Anxiety Disorders, Department of Psychiatry, University of Pennsylvania School of Meidicine, Philadelphia, USA
    Psychiatr Clin North Am 24:1-17. 2001
    ..7. Symptoms that some clinicians consider cardinal for a diagnosis of GAD, such as extreme worry, obsessive rumination, and somatization, also are present in other disorders, such as MDD. (ABSTRACT TRUNCATED)..
  17. ncbi request reprint Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder
    K Rickels
    Psychopharmacology Unit, University Science Center, University of Pennsylvania 19104 2649, USA
    Am J Psychiatry 157:968-74. 2000
    ..This study evaluated the efficacy and safety of fixed doses of once-daily extended-release (XR) venlafaxine in outpatients with generalized anxiety disorder without concomitant major depressive disorder...
  18. ncbi request reprint Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial
    E W Freeman
    Department of Obstetrics Gynecology, School of Medicine, University of Pennsylvania, Philadelphia 19104, USA
    Arch Gen Psychiatry 56:932-9. 1999
    ....
  19. ncbi request reprint Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation
    K Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia
    Arch Gen Psychiatry 47:899-907. 1990
    ..These results provide a detailed picture of the symptoms, time course, and multidimensional determinants of the benzodiazepine withdrawal syndrome...
  20. ncbi request reprint Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone
    K Rickels
    Department of Psychiatry, Psychopharmacology, University of Pennsylvania, Philadelphia
    Arch Gen Psychiatry 45:444-50. 1988
    ..For the buspirone group, a higher dropout rate raised questions about patient satisfaction with therapy in this rather chronically anxious population...
  21. ncbi request reprint The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial
    E Schweizer
    Department of Psychiatry, University of Pennsylvania, Philadelphia 19104-3309, USA
    Int Clin Psychopharmacol 16:137-43. 2001
    ..While some patients clearly benefit from higher doses, the results of the current study are consistent with the lack of any evidence for a dose-response curve with sertraline in the treatment of depression...
  22. ncbi request reprint Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial
    Moira Rynn
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Depress Anxiety 25:182-9. 2008
    ..Duloxetine was an efficacious, safe, and well-tolerated treatment that resulted in clinically significant improvements in symptom severity and functioning for patients with GAD...
  23. ncbi request reprint Clorazepate and lorazepam: clinical improvement and rebound anxiety
    K Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia
    Am J Psychiatry 145:312-7. 1988
    ..The clinical relevance of these findings is discussed...
  24. ncbi request reprint Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant
    E W Freeman
    Department of Obstetrics Gynecology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    J Clin Psychopharmacol 19:3-8. 1999
    ....
  25. ncbi request reprint Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania Medical Center, Philadelphia 19104 3309, USA
    Am J Psychiatry 160:749-56. 2003
    ..This study assessed the efficacy of two fixed doses of paroxetine in the treatment of generalized anxiety disorder...
  26. ncbi request reprint Characteristics of placebo responses in medical treatment of premenstrual syndrome
    E W Freeman
    Department of Obstetrics Gynecology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Am J Psychiatry 156:1403-8. 1999
    ..This study characterizes the responses to placebo medication of patients with premenstrual syndrome (PMS) who were randomly assigned in controlled treatment trials. Possible predictors of placebo response were also examined...
  27. ncbi request reprint Paroxetine in the treatment of generalised anxiety disorder
    Steven H Snyderman
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
    Expert Opin Pharmacother 5:1799-806. 2004
    ....
  28. ncbi request reprint Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder
    M A Rynn
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Am J Psychiatry 158:2008-14. 2001
    ..The study compared the safety and efficacy of sertraline, a selective serotonin reuptake inhibitor, and placebo in the treatment of generalized anxiety disorder in children and adolescents...
  29. doi request reprint Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder
    F W Lohoff
    1 Psychiatric Pharmacogenetics Laboratory, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA 2 Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Pharmacogenomics J 13:464-9. 2013
    ..0001). Single-marker analysis only showed HAM-A differences of 4.3 (5-HTTLPR/rs25531: La/La versus La/S+S/S) and 4.8 (rs7997012: G/G+G/A versus A/A), showing for the first time a significant gene-gene interaction between these markers. ..
  30. ncbi request reprint Clinical overview of serotonin reuptake inhibitors
    K Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia
    J Clin Psychiatry 51:9-12. 1990
    ..Although serotonin reuptake inhibitors have not replaced the tricyclics, they are a useful addition to the variety of drugs currently used for the treatment of depression...
  31. ncbi request reprint Reliability and validity of a daily diary for premenstrual syndrome
    E W Freeman
    Department of Psychiatry, University of Pennsylvania Medical Center, Philadelphia 19104 4283, USA
    Psychiatry Res 65:97-106. 1996
    ..The moderate correlations of the DSR with other standard symptom measures add to the evidence that PMS overlaps with other mood disorders at the premenstrual time but is not simply a brief depression or a truncated anxiety disorder...
  32. ncbi request reprint Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006
    ..This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD)...
  33. ncbi request reprint Venlafaxine in the treatment of premenstrual dysphoric disorder
    E W Freeman
    Department of Obstetrics Gynecology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Obstet Gynecol 98:737-44. 2001
    ..To evaluate the efficacy and safety of venlafaxine, a new-generation antidepressant that selectively inhibits serotonin and norepinephrine reuptake, in the treatment of premenstrual dysphoric disorder (PMDD)...
  34. pmc Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertraline
    Ellen W Freeman
    Department of Obstetrics Gynecology, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104 5509, USA
    Arch Gen Psychiatry 66:537-44. 2009
    ..The duration of treatment after achieving a satisfactory response is unknown in the treatment of premenstrual syndrome. This information is needed in view of the improvement provided by medication vs the adverse effects and costs of drugs...
  35. ncbi request reprint Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study
    Falk W Lohoff
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 30:185-9. 2010
    ....
  36. doi request reprint A survey of patient acceptability of repetitive transcranial magnetic stimulation (TMS) during pregnancy
    Deborah R Kim
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, United States
    J Affect Disord 129:385-90. 2011
    ..Given the novelty of TMS, we sought to assess whether patient acceptability would be a barrier to enrolling pregnant women in TMS studies...
  37. ncbi request reprint Desvenlafaxine succinate for the treatment of major depressive disorder
    Falk W Lohoff
    University of Pennsylvania School of Medicine Mood and Anxiety Disorders Section, Department of Psychiatry, Center for Neurobiology and Behavior, Translational Research Laboratories, Philadelphia, PA 19104, USA
    Expert Opin Pharmacother 9:2129-36. 2008
    ..Additional studies, in particular head-to-head comparison to other antidepressants and long-term treatment studies, will be necessary to comprehensively evaluate DVS safety and efficacy for clinical practice...
  38. pmc Core symptoms that discriminate premenstrual syndrome
    Ellen W Freeman
    Department of Obstetrics Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Womens Health (Larchmt) 20:29-35. 2011
    ..To identify core symptoms that discriminate premenstrual syndrome (PMS) in prospective daily diary ratings and determine the association of these symptoms with functional impairment...
  39. ncbi request reprint Allopregnanolone levels and symptom improvement in severe premenstrual syndrome
    Ellen W Freeman
    Department of Obstetrics Gynecology, University of Pennsylvania, Philadelphia 19104, USA
    J Clin Psychopharmacol 22:516-20. 2002
    ....
  40. ncbi request reprint Early response and 8-week treatment outcome in GAD
    Moira Rynn
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Depress Anxiety 23:461-5. 2006
    ..001). Early improvement was a strong predictor for treatment outcome irrespective of whether active medication or placebo was the treatment agent...
  41. ncbi request reprint Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database
    Karl Rickels
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19104 3309, USA
    J Clin Psychiatry 67:41-7. 2006
    ..This article reviews the efficacy and tolerability of paroxetine in the short- and long-term treatment of GAD including remission data...
  42. ncbi request reprint Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder
    Ellen W Freeman
    Department of Obstetrics Gynecology, University of Pennsylvania School of Medicine, Philadelphia 19104 5509, USA
    Am J Psychiatry 161:343-51. 2004
    ....
  43. ncbi request reprint Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy
    Moira Rynn
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3309, USA
    J Clin Psychopharmacol 23:505-8. 2003
    ..Neither discontinuation severity nor taper-free status 12 weeks posttaper differed between the 3 treatment groups...
  44. doi request reprint Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder
    F W Lohoff
    Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Pharmacogenomics J 13:21-6. 2013
    ..Future studies with larger sample sizes are necessary to further characterize this effect in treatment response to antidepressants in GAD...
  45. ncbi request reprint Abnormal salivary cortisol levels in social phobic patients in response to acute psychological but not physical stress
    P M Furlan
    Department of Psychiatry, Behavioral Psychopharmacology Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6140, USA
    Biol Psychiatry 50:254-9. 2001
    ..These results suggest adaptation of distinct biological processes specific to different stressful conditions in social phobia...
  46. ncbi request reprint A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
    Amir Garakani
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10075, USA
    Int Clin Psychopharmacol 23:269-75. 2008
    ..The combination of quetiapine and fluoxetine, however, improved sleep over fluoxetine alone over the first few weeks of treatment...
  47. ncbi request reprint A pilot naturalistic follow-up of extended sertraline treatment for severe premenstrual syndrome
    Ellen W Freeman
    J Clin Psychopharmacol 24:351-3. 2004
  48. ncbi request reprint Open-label pilot study of ziprasidone for refractory generalized anxiety disorder
    Steven H Snyderman
    J Clin Psychopharmacol 25:497-9. 2005
  49. ncbi request reprint The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study
    Mark H Pollack
    Anxiety Disorders Program, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
    J Clin Psychiatry 66:1401-8. 2005
    ..To evaluate the efficacy and tolerability of tiagabine, a selective gamma-aminobutyric acid (GABA) reuptake inhibitor, in adults with generalized anxiety disorder (GAD)...
  50. ncbi request reprint Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30307, USA
    J Clin Psychopharmacol 27:614-9. 2007
    ..Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue...

Research Grants5

  1. Short-Term vs Long-Term Treatment for GAD
    Karl Rickels; Fiscal Year: 2004
    ..12 months). The proposed study will provide much needed data, lacking from the literature, about the value of long term medication treatment of patients with a DSM-IV GAD diagnosis. ..
  2. Short-Term vs Long-Term Treatment for GAD
    Karl Rickels; Fiscal Year: 2005
    ..12 months). The proposed study will provide much needed data, lacking from the literature, about the value of long term medication treatment of patients with a DSM-IV GAD diagnosis. ..
  3. Short-Term vs Long-Term Treatment for GAD
    Karl Rickels; Fiscal Year: 2006
    ..12 months). The proposed study will provide much needed data, lacking from the literature, about the value of long term medication treatment of patients with a DSM-IV GAD diagnosis. ..
  4. Short-Term vs Long-Term Treatment for GAD
    Karl Rickels; Fiscal Year: 2007
    ..12 months). The proposed study will provide much needed data, lacking from the literature, about the value of long term medication treatment of patients with a DSM-IV GAD diagnosis. ..